StockWatch
·
AMANTA HEALTHCARE · Q2 FY27 · THE VERDICT

Strong Quarter, Scaled-Back Outlook — The Real Number Is Lower

Amanta delivered Q2 revenue growth of 17.3% and EBITDA margins of 21.6%, but revised FY27 guidance down from ₹440 to ₹420–430 Cr due to SteriPort Line 3 commissioning delays. The earnings call confirms both: solid organic momentum and a credibility dent from the prior miss.

Q2 FY27 resultsAMANTAAmanta Healthcare Ltd09 Nov 2026 · 6 min read
Q2 Revenue

₹83.1 Cr

+17.3% YoY

FY27 Guide

₹420–430 Cr

−₹20 Cr vs prior

EBITDA margin

21.6%

vs polymer +70% hike

Debt-to-equity

1.1x

improved from 3.5x

Amanta delivered a credible Q2 — revenue of ₹83.1 Cr (+17.3% YoY), EBITDA margin of 21.6% despite polymers spiking >70%, and solid cash generation to support debt reduction. But the earnings call revealed the catch: the full-year outlook was scaled back from ~₹440 Cr to ₹420–430 Cr, a 2–4.5% downgrade driven by SteriPort Line 3 commissioning delays (late September vs. expected late August). That gap between the strong print and the weaker guide is the story of the quarter.

Where the profit came from

The reported PAT of ₹4.9 Cr in Q2 rose 303% YoY, but this masks a critical point: H1 PAT was only up 12% YoY. Management confused the narrative on the call, citing a 26% YoY growth figure (which applies to H1, not Q2), suggesting Q1 was materially weaker. EBITDA margin at 21.6% was held intact despite polymer headwinds, achieved through product mix realization and cost discipline — a genuine operational achievement, not accounting sleight. The solar plant (10.8 MW, operational since Q1 FY27) is delivering ₹9 Cr in annual power savings, a structural competitive advantage going forward.

Management's claims vs. what holds up

Top line grew 17% YoY in Q2; revenue ₹83.1 Cr

Delivered revenue ₹83.1 Cr, YoY +17.3%

Supported

PAT up 26% YoY

Q2 PAT up 303% YoY; H1 PAT up 12% YoY. Management cited H1 growth on a Q2 call.

Contradicted (confusion between Q2 and H1)

EBITDA margin 21.6% despite polymer headwinds

Delivered OPM 20.7%; EBITDA margin claim plausible via product mix shift and cost discipline

Supported

FY27 revenue ₹420–430 Cr annualized

Prior guidance ~₹440 Cr (baseline ₹370 + Line 3 ₹70 for 7 months); new guide 2–4.5% lower due to Line 3 delay

Guidance cut (miss vs prior)

SteriPort Line 3 at 100% utilization by Nov 20

52–55% utilization as of call; ramp to 100% by target date is plausible

Supported

What changed on this call

Key moves from the prior quarter
  • FY27 revenue guidance lowered from ~₹440 Cr to ₹420–430 Cr (−2–4.5%)

  • SteriPort Line 3 confirmed ₹110 Cr annual run-rate at full capacity; ₹60 Cr expected in FY27

  • SVP facility completion confirmed March 2027; 20-product inhalation pipeline advanced

  • Debt-to-equity improved to 1.1x (from 3.5x in FY23); balance sheet trajectory unlocked

  • Solar plant (10.8 MW) fully operational; ₹9 Cr annual power cost saving locked in

The bull-bear ledger

  • Q2 revenue growth of 17.3% + EBITDA margin 21.6% held firm despite >70% polymer price hike

  • SteriPort Line 3 ramp-up on track; ₹110 Cr annual capacity will add ~₹50–60 Cr to revenue post-ramp

  • Debt-to-equity 3.5x → 1.1x in 3 years; net debt path to ₹100 Cr by FY29 credible

  • Solar cost advantage (₹9 Cr/year) is structural and defensible; competitive moat widening

  • FY27 guidance cut from ₹440 to ₹420–430 Cr is a 2–4.5% miss; credibility dent on prior call

  • SVP execution risk is material; management itself called inhalation revenue 'very speculative' (₹16 Cr FY28 floor)

  • Regulatory pricing pressure (NPPA/NLEM) targeting distribution margins; retail profitability at risk

  • Polymer price volatility ongoing; margin cushion already absorbed; limited hedge further

  • PAT growth narrative confused on call (Q2 +303% vs H1 +12%); management clarity lacked

Ranked risks — what should concern a holder

Risks, ranked by severity and holder impact

SVP execution & product commercialization

HIGH

Facility March 2027 completion; product transfer & regulatory approvals uncertain (6–9 mo timeline). Inhalation revenue unquantified; management called it 'very speculative' (₹16 Cr FY28 floor). If SVP slips or ramps slowly, 2-yr growth target (20%+ CAGR) is at risk.

Regulatory pricing (NPPA/NLEM) margin compression

MEDIUM

NPPA/NLEM focused on reducing distribution margins, not manufacturing. Amanta is retail-dependent; hospital margin pressure will directly impact bottom-line profitability. No clear hedge available.

FY27 guidance miss and credibility

MEDIUM

Revised FY27 revenue down 2–4.5% from prior ~₹440 Cr to ₹420–430 Cr due to SteriPort Line 3 commissioning delay. Raises questions on execution discipline and prior forecasting quality.

Polymer price volatility and margin sustainability

MEDIUM

Polymers spiked >70% and remain volatile (oil-linked). EBITDA margin of 21.6% absorbed the spike via product mix, but limited cushion for further volatility. Normalization expected 3–6 months but unquantified.

Customer concentration in ICU/critical care

LOW

SteriPort demand concentrated in ICU, high-dependency units. Hospital consolidation or shift to lower-value products could pressure volumes/pricing. Diversification via inhalation/ophthalmics is multi-year play.

How the street is positioned — and what it signals

Amanta's stock is trading at ₹195 (as of 2026-11-06), in a bullish trend: above its 20-day (₹174.39), 50-day (₹185.22), and 200-day (₹146.01) moving averages. RSI of 59.5 signals neutral momentum (neither overbought nor oversold). The stock is +109.45% off its 52-week low (₹93.1) but only −7.14% from its all-time high of ₹210. Volume is increasing, suggesting renewed interest.

Institutional flows are mixed and trending cautious. FII ownership has declined from 1.10% (Q3 FY26) to 0.43% (Q1 FY27) — a consistent trim over the past two quarters. DII ownership is stable at ~12.9%, and promoter stake holds steady at 63.80%. The FII exit suggests foreign institutions are taking profits or reassessing valuation after the strong run. Bulk deal activity over the past six months shows a balanced mix of buys and sells in the ₹156–159 range — no panic selling, but no sustained insider or large-block accumulation either. The absence of promoter selling near the highs is a positive signal.

Valuation context: The stock's +109% rally off lows and position near all-time highs suggests the market has already priced much of the bull case — the SteriPort capacity ramp and near-term catalysts are largely reflected in the current price. The FII exit may signal that foreign funds see limited upside from current levels absent SVP execution. For a holder, this matters: the stock is fairly valued for Q2 delivery (17.3% growth, resilient margins), but the 2-yr thesis (20%+ CAGR, SVP ramp) is speculative and likely already in the price.

The debate

What to watch next

Three concrete things that resolve the debate by Q3–Q4
  • 1 · SteriPort Line 3 utilization ramp (target: 100% by Nov 20, 2026)

    Management stated 52–55% utilization as of the call. If the line hits 100% by the target date, that unlocks ~₹5 Cr in annual capacity and confirms the ₹110 Cr annual run-rate claim. This is the near-term proof point for FY27 guidance credibility.

  • 2 · Q3–Q4 FY27 run-rate and FY27 full-year delivery

    The current guide is ₹420–430 Cr annualized. If October–November run-rate (post-Line 3 ramp) confirms this, confidence in the lower guide is justified, and management's credibility is restored. A miss here (below ₹420 Cr annualized) would be a second warning on forecasting quality.

  • 3 · SVP facility construction progress and inhalation product transfer (target: March 2027 completion)

    The facility must complete on time, and the first 2–3 inhalation products must transfer and clear regulatory approvals by Q1 FY28. Any slip here pushes the 20%+ CAGR target further out. Management guidance of 'very speculative' revenue means the market will scrutinize every milestone. Hit March 2027 on time → credibility restored. Slip → stock pressure.

The number to track from here

FY27 full-year revenue (₹420–430 Cr). This is the immediate credibility test. Miss it (again), and the 20%+ CAGR thesis loses conviction. Hit it, and the near-term story (SteriPort ramp) is intact. The organic growth trajectory — not reported PAT, which is muddied by polymer/energy volatility — is what separates a steady operator from a step-change story.

Amanta is a steady-execution story with a strong near-term catalyst (SteriPort Line 3 ramp, solar savings) and meaningful medium-term optionality (SVP, inhalation). The Q2 quarter confirms the near-term thesis: solid growth, resilient margins, improving balance sheet. But the FY27 guidance cut is a credibility dent, and the market has largely priced the SteriPort story into the stock (up 109% off lows, near all-time highs). SVP execution is the real opportunity — and the real risk. Management's candid admission that inhalation revenue is 'very speculative' is honest, but it also signals execution uncertainty that will take time to resolve. For now, this is a hold for SteriPort catalysts and balance-sheet improvement — not a buy on speculative SVP upside. The next 2–3 quarters will test whether Amanta is a 20%+ CAGR story or a steady 10–15% organic grower with occasional outlier years.

Informational and educational content only. Not investment advice.